McKinsey published an interview with Joseph Jimenez the CEO of Novartis on the theme of digitizing medicine (or is that medicines?).

Key takeaways ….biology and technology coming together as in Novartis’ work with Google on their smart contact lens … shifting from a transactional (e.g. pill as product) approach to an outcomes-based approach .

And, though it reads a bit garbled, a claim that new drugs will cost more and raise the medicines bill for healthcare, but their health benefits will drive many other costs out of the rest of the system.